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Spinal cord injuries (SCIs) represent a variety of conditions related to the damage of
the spinal cord with consequent musculoskeletal repercussions. The bone and muscle
tissues share several catabolic pathways that lead to variable degrees of disability in
SCI patients. In this review article, we provide a comprehensive characterization of the
available treatment options targeting the skeleton and the bone in the setting of SCI.
Among the pharmacological intervention, bisphosphonates, anti-sclerostin monoclonal
antibodies, hydrogen sulfide, parathyroid hormone, and RANKL pathway inhibitors
represent valuable options for treating bone alterations. Loss phenomena at the level
of the muscle can be counteracted with testosterone, anabolic-androgenic steroids,
and selective androgen receptor modulators. Exercise and physical therapy are valuable
strategies to increase bone and muscle mass. Nutritional interventions could enhance
SCI treatment, particularly in the setting of synergistic and multidisciplinary interventions,
but there are no specific guidelines available to date. The development of multidisciplinary
recommendations is required for a proper clinical management of SCI patients.
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INTRODUCTION
Spinal cord injuries (SCIs) encompass a spectrum of conditions associated with modifications in
the function of both central and peripheral nervous systems. Due to the crucial role of the spinal
cord in linking the brain with the body, these alterations may lead to dramatic consequences in
terms of motor, sensitive, and visceral controls (1).
A complex variety of biological pathways arising in both bone and muscle tissues plays a
clinically relevant role in SCIs. Hence, these patients experience important changes in the bones
(e.g., osteoporosis) that cause a significantly increased risk of fractures, even after minor traumas
(e.g., transferring or sitting) (2, 3). These clinical conditions lead to further immobilization of the
patient, increased spasticity, pressure ulcers, and in general worsened disability (3). Bone tissue
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loss after SCIs starts rapidly and grows in the first 2 years
after the injury (4). In chronic SCIs, the skeleton of the
lower third of the femur and upper third of the tibia may be
subjected to 70% of decreased mineral density (5, 6). Muscle
modifications further increase the patients’ fragility because
they lead to immobilization, increased fracture risk, pressure
sores, thrombosis, overpressure, chronic pain, and psychosocial
issues (7). The loss of mass in the muscles below the SCI is
remarkable, reaching up to 40% in the first 2 years after the
injury (8). Regrettably, despite muscle atrophy is macroscopically
more evident than osteoporosis, this phenomenon is often
underestimated (7).
In this scenario, understanding the biological interplay of the
bone andmuscle tissues is crucial for proper clinical management
of SCIs. Here, we sought to provide a comprehensive portrait of
the potentials and limitations of the various treatment options
available (or proposed) to date for both osteoporosis and muscle
atrophy occurring after SCIs.
PHARMACOLOGICAL APPROACHES TO
BONE ALTERATIONS
The use of single, combination, or sequential therapy protocols
in the management of bone alterations in SCI is a matter
of controversy. After the achievement of clinical benefits,
the discontinuation of osteoanabolic treatments could result
in a rapid loss of the newly gained bone (9–12). For
this reason, clinicians are recommended to promptly start
other anti-resorptive therapies after osteoanabolic interventions
discontinuation. At present, there are no widely adopted
guidelines about the most reliable pharmacological strategy.
Bisphosphonates
Bisphosphonates are the most used class of drugs in the
prevention and treatment of osteoporosis (13). Several
studies have assessed the efficacy of these anti-resorptive
drugs in acute and chronic SCIs. A meta-analysis provided
circumstantial evidence to suggest that the early administration
of bisphosphonates can reduce SCI-related osteoporosis (13).
It should be taken into account, however, that this hypothesis
is biased by the small sample size of the few clinical trials
available to date (14). Moreover, despite many groups showed
that bisphosphonates may be particularly effective at the hip
level, only a few information is currently available on their role
at the distal third of the femur and/or at the proximal third
of the tibia. A recent, non-randomized study on the yearly
administration of zoledronic acid failed to show an improvement
in the bone mass density (BMD) at this level, being associated,
on the contrary, with a reduction in bone mass (15). Therefore,
several doubts exist about the efficacy and the safety profile of
bisphosphonates in patients with SCI. Due to these issues, at the
present time, prophylaxis of osteoporosis with bisphosphonates
in SCI remains an interesting area of research but it is not yet
ready for prime time (16). On the other hand, alendronate
showed significant results in maintaining or even increase BMD
after previous osteoanabolic interventions (9, 10, 17). These
observations suggest that a sequential therapy scheme with
alendronate after teriparatide treatment is likely to prevent bone
loss, increase bone mass, and preserve bone strength at the spine
and hip in SCI patients.
Anti-sclerostin Antibodies
Murine SCI models showed that anti-sclerostin antibodies could
preserve the osteocyte morphology and structure, blocking
the skeletal deterioration after either motor-incomplete (18)
or motor-complete SCI (15). A recent study assessed the
efficacy of these antibodies in reversing the bone loss in a
rodent model after motor-complete SCI (19). Animals treated
with 25 mg/kg/week for 8 weeks (starting at 12 weeks after
SCI) showed a significant increase in BMD, structure, and
mechanical strength. Anti-sclerostin antibodies acted in the case
group through osteoclastogenesis inhibition and concomitant
osteoblastogenesis stimulation. Untreated SCI mice showed a
significant reduction in BMD and the deterioration of bone
structure at the distal femoral metaphysis. These data suggest that
sclerostin antagonism might be a viable therapeutic option not
only to prevent bone loss after acute SCI but also in the chronic
setting (19).
Hydrogen Sulfide
Hydrogen sulfide (H2S) is a colorless and poisonous gas acting
as a gas transmitter to regulate different signaling pathways (20).
It has been recently hypothesized that abnormal H2S metabolism
could be linked to defects in bone homeostasis (21). Treatment
with an H2S donor (GYY4137) increase bone formation,
preventing the loss of trabecular bone in case of estrogen
deficiency (21). Whether H2S might have anti-osteoporosis
effectiveness in motor-complete SCI models has recently been
investigated (22). Rats were treated with an intraperitoneal
injection of 0.1 ml/kg/day of 0.28 mol/l NaHS (a donor of H2S)
for 2 weeks. They showed an increase of femoral and tibial BMD,
bone volume fraction (bone volume/total, BV/TV), trabecular
thickness and number, and a concomitant reduction of trabecular
separation in proximal tibiae. Furthermore, rats treated with
NaHS showed an increased mineral apposition rate (MAR), bone
formation rate (BFR), and osteoblast proliferation (22). Given
that an increased ROS production is one of the mainmechanisms
related to bone and muscle modifications after SCI, all these
results suggest a potential role of H2S treatment in SCI-related
bone loss.
Parathyroid Hormone
Parathyroid hormone (PTH) is a well-known player in calcium
metabolism. The subcutaneous intermittent administration of
PTHhas been used for two decades as a valid anabolic therapeutic
agent for osteoporosis treatment (23, 24). A recent study
investigated whether PTH administrationmight reduce bone loss
in SCI female mice (25). PTH (80 mg/kg) or vehicle was injected
subcutaneously daily for 35 days. Isolated tibias and femurs were
assessed through microcomputed tomography scanning (micro-
CT), histology, and serum bone turnover markers. SCI-vehicle
animals reported a 49% reduction in fractional trabecular bone
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volume and 18% in trabecular thickness compared to sham-
vehicle controls. Moreover, the authors found 15% lower femoral
cortical thickness and 16% higher cortical porosity in SCI-vehicle
animals compared to sham ones. PTH treatment restored 78%
of bone volume in SCI animals. In addition, histomorphometry
showed a marked decline in osteoblast and osteoclast number
and a 35% reduction in bone formation rate. On the other hand,
in SCI-PTH animals the number of osteoblasts and osteoclasts
was preserved, and the bone formation rate was enhanced.
These results suggest a potential therapeutic role of subcutaneous
intermittent PTH treatment in acute SCI patients, however to
date, data in humans are lacking. Recently, abaloparatide, a
parathyroid hormone-related protein (PTHrP), was approved by
Food and Drug Administration (FDA) for the treatment of severe
post-menopausal osteoporosis (26). A recent study performed by
Sahbani et al. compared abaloparatide to teriparatide on bone
structure, turnover, and levels of RANKL and OPG on wild-type
female mice (27). The authors showed that 20–80 µg/kg/day of
abaloparatide for 30 days resulted in a significant increase (13%)
in trabecular bone thickness and lowered the RANKL/OPG ratio.
In light of these results, abaloparatide could be a promising
therapeutic agent to counter osteoporosis, and future studies
could investigate its efficacy also in SCI patients.
Denosumab
The receptor activator of nuclear factor-kB ligand
(RANKL)/osteoprotegerin (OPG) system is one of the main
regulators of bone remodeling (28). Denosumab, a RANKL
pathway inhibitor monoclonal antibody, has been widely used
in the treatment of osteoporosis (29–33). Increased osteoblast
expression of RANKL has been previously observed in unloading
conditions, such as SCI, resulting in an increased RANKL/OPG
ratio (34–38). These observations have suggested a potential
therapeutic role of denosumab in SCI-induced bone loss.
Only one work investigated the effects of denosumab on acute
SCI in humans, with promising results (33). Compared to
RANKLS-positive patients with detectable RANKL, those with
undetectable RANKL levels showed better responses both in
terms of femoral BMD increase and bone reabsorption markers
decrease. Therefore, denosumab has been regarded as a drug
potentially able to prevent SCI-related bone loss (38).
PHARMACOLOGICAL APPROACHES TO
MUSCLE ALTERATIONS
To date, there is no robust evidence about local pharmacological
agents that can be used to counteract the muscle loss after SCI.
Most data currently available are derived from studies on healthy
subjects or patients with chronic conditions of which some (e.g.,
cachexia and wasting) share some pathophysiological pathways
with SCI. In this setting, androgens have been extensively
studied, either in animal models and in humans. Particularly,
testosterone and anabolic-androgenic steroids (AAS) such
as nandrolone, as well as the selective androgen receptor
modulators (SARMs), have been proposed as pharmacological
strategies to hinder the loss phenomena at the musculoskeletal
level in different chronic illnesses, such as immunodeficiency,
long term glucocorticoid treatment, and aging (39, 40). Data
about safety and efficacy on the lean mass increase are available
in healthy subjects, aged women, and men and in cancer-
related cachexia (40–42). The main factor supporting the use
of SARMs instead of testosterone is the tissue selectivity and
good tolerability with negligible adverse events. The evidence
emerging from cancer cachexia patients suggests a theoretical
use of SARMs also in SCI-induced atrophy. The observation
that a substantial proportion of male and female individuals
experience hypogonadism after acute or chronic SCI represents
the rationale of using testosterone and AAS in these patients
(43, 44). Several studies have shown a significant effect of
testosterone and nandrolone against muscle atrophy in rodents
(45, 46). These results have been partially replicated in a small
trial on SCI patients, in which the Authors showed that the
correction of hypogonadism by 12 months of testosterone
therapy can increase lean tissue mass for the whole body,
leg, and arm (47). A recent randomized clinical trial showed
that the combination of electrical stimulation exercise training
and testosterone replacement therapy can increase muscle mass
in the lower extremities of SCI patients (48). This effect
was not present in patients only treated with testosterone
without exercise.
EXERCISE AND PHYSICAL THERAPY
Exercise is the first treatment to increase muscle mass and there
is growing evidence that the basic mechanisms that regulate
muscle hypertrophy can be used to counteract disuse atrophy
(40). The mechanisms by which physical exercise induce muscle
hypertrophy have not been completely elucidated. The IGF-
1/PIP3K/Akt pathway, even if it is considered a key mediator
of normal muscle development, is not able to explain alone
the exercise-induced muscle hypertrophy (49). On the other
hand, mTORC1 appears to be crucial in load-induced muscle
growth (50), as phospholipase D and phosphatidic acid that
active mTORC1 (51). In a rodent model, exercise can protect
the skeletal muscle against oxidative stress and proteolysis (52).
Eccentric contractions can increase phosphatidic acid levels and
inducemuscle growth onmice, confirming the importance of this
mechanism (53).
Physical Exercise and Treadmill
A recent study performed on 42 male Wistar rats showed that
stretching is helpful for the correction of contractures after
SCI (54). In addition, the Authors observed that heat is more
beneficial than cold to increase the effectiveness of stretching
in terms of restoring range of motion and decreasing muscle
contractures. Lately, it has been demonstrated that 9-week
treadmill training in mice affected by incomplete SCI is effective
in preventing atrophy of fast-twitch muscles, with limited effects
on slow-twitch muscles and muscle fiber type composition
of medial gastrocnemius, soleus, and tibialis anterior (55). In
healthy humans, several studies have shown that eccentric
training (i.e., motion of a muscle while it is lengthening under
load) can increase muscle mass and muscle strength more than
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concentric exercise [i.e., shortening of a muscle while it is
contracting; (56)]. Exercise can also reduce the expression and
production of myostatin (57–59).
Functional Electrical Stimulation
Rowing Exercise
In the early 1990s, functional electrical stimulation (FES)
rowing exercise has been developed as an aerobic training
program for SCI patients (60, 61). This approach consists
of coordinated voluntary upper body exercise combined with
electrical stimulation of the leg large muscle groups to produce a
near-full-body exercise. Recently Lambach et al. (62) performed
a study on four adults with recent (<2 years) traumatic, motor
complete SCI, undergoing a 90-session FES rowing exercise
program, and attending 30-min FES training sessions for 3
times/week. They showed that trabecular BMD in the femur
and tibia decreased for all participants after 30 sessions, with
a rate of loss slowed or reversed between the 30th and 60th
sessions, with the little-to-no bone loss for most participants
during the period intercurrent from 60th and 90th sessions.
However, further studies with larger cohorts of participants are
needed to confirm the observation of FES rowing exercise in
SCI individuals.
Whole-Body Vibration
In the recent past, whole-body vibration (WBV) effects on bone
architecture after SCI have been investigated with inconsistent
results. In 2016, Dudley-Javoroski et al. showed that 12 months
of vibration training did not preserve BMD or trabecular
architecture in subjects affected by chronic SCI, showing bone
tissue insensitivity to mechanical loading interventions (63).
These results are not in line with the previous studies performed
on rats, where WBV seemed to attenuate the bone loss that
commonly occurs during the early acute stages after SCI (64).
On the other hand, WBV seems to have a positive role
in ankle spasticity, balance, and walking ability in patients
with incomplete SCI at the cervical level (65), suggesting a
potential synergistic role with other therapeutic interventions.
Only a handful of studies investigated the use of WBV to
improve muscle function in patients with SCI (66). Among
them, a single study evaluated functional parameters such as
walking speed (67), whereas the others took into account only
evaluated electrophysiological data. One study failed to show
any modifications in muscle cross-sectional area or muscle
density after 40 weeks of treatment (68). It should be noted that
available studies have been conducted on small sample sizes,
with heterogeneous protocols (intensity, duration, frequencies).
Therefore, no strong conclusions can be drawn at present time.
FIGURE 1 | Representative computed tomography (CT) scans before and after a 16 weeks epidural electrical stimulation (EES) protocol in two patients with spinal
cord injury. (A) Patient 1 before EES; (B) patient 1 after EES; (C) patient 2 before EES; (D) patient 2 after EES. The images have been kindly provided by Prof. G.
Courtine and J. Bloch.
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Epidural Electrical Stimulation
Epidural electrical stimulation (ESS) is a promising technique for
improving motor recovery in chronic patients with SCI (69, 70).
Preliminary results showed that the application of ESS improving
both motor control and muscle mass in the lower extremity of
patients with severe paralysis or plegia (Figure 1). This effect
could be ascribed to the stimulation of the posterior roots,
enabling muscle contraction (69). This mechanism is different
from that obtained by FES since muscle contraction is mainly
indirect. Interestingly, spasticity, which is another indirect, reflex
activity in patients with SCI, is associated with partially preserved
muscle mass (70).
NUTRITIONAL INTERVENTIONS
Despite a healthy diet is recommended in SCI individuals, there
is a substantial lack of nutritional guidelines for these patients
(71–73). In addition, their altered body composition limits the
accurate measurement of the energy intake and the need (74, 75).
A recent systematic review and meta-analysis investigated the
nutritional status of adult subjects with chronic SCI (76, 77).
The authors showed that mean total energy (1,876 kcal/day),
fiber intake (17 g/day), vitamins A, B5, B7, B9, D, E, potassium,
and calcium were below the levels recommended by the
United States Department of Agriculture (USDA). On the other
hand, protein (319 kcal/day) and carbohydrate (969 kcal/day)
intake and vitamins B1, B2, B3, B12, C, K, sodium, phosphorus,
copper, and zinc exceeded the USDA recommendation. Of
note, the fat intake (663 kcal/day), vitamin B6, iron, and
magnesium were within limits (77). Supplementation with
creatine to improve muscle strength in patients with chronic
SCI has been also evaluated, with conflicting results. Two
studies found no effect of creatine supplementation either on
hand strength (78) or wheelchair performance (79), while two
studies found some positive effects on upper extremity strength
and function (80, 81). All these diverse correlations highlight
the need for a prompt and precise nutritional assessment in
SCI patients, focusing on correct daily energy intake and a
higher fiber and micronutrient intake (i.e., vitamin D and
calcium). Future studies are required to investigate not only
the nutritional health status but also the adequate nutritional




There is no unequivocal evidence about the superiority
of a single therapeutic intervention to counteract the
modifications in bone and muscle tissues after SCI. Given
the complex and multifaceted nature of these conditions,
it is conceivable that the best therapeutic strategy consists
of the synergistic use of several different interventions in
order to optimize the outcome at bone and muscle level in
SCI patients.
Zoledronic Acid Plus FES Rowing Exercise
Considering the promising role of FES rowing exercise in
promoting muscle contraction with combined mechanical
loading of lower limb long bones in SCI patients, a therapeutic
synergism with drugs acting at the bone level has been proposed
(82). This combined strategy could induce both bone resorption
inhibition and bone neoformation stimulation. A randomized
clinical trial comparing FES-rowing alone with FES-rowing plus
zoledronic acid (a powerful bone anti-resorptive drug), have
been carried out to investigate the impact of bone health in
SCI (82). The latter group had significantly greater cortical
bone volume (CBV) and cortical thickness index (CTI) at
both distal femoral and proximal tibial metaphyses, compared
to the FES-rowing-only group. In the rowing-only group of
patients, the cortical compressive strength index (CSI) at the
tibial metaphysis showed significant variations based on the
amount of exercise performed. These data showed that a
combined antiresorptive and FES rowing exercise therapy might
improve bone quality and geometry, suggesting that multimodal
therapeutic interventions could be beneficial in counteracting the
bone and muscle modifications.
Teriparatide and Whole-Body Vibration
Teriparatide, a 34 amino acid peptide representing the N-
terminal bioactive portion of human PTH, is the only anabolic
agent approved to enhance bone mass and prevent fragility
fractures (83, 84). A recent randomized, double-blind, multi-
center, parallel-group clinical trial on 61 individuals with chronic
SCI and low bone mass showed that patients treated with
teriparatide 20 µg/day showed a significant increase in areal
BMD (aBMD) at the spine level after the first 12 months in
both groups treated (4.8–5.5%) regardless of the simultaneous
administration of WBV or sham WBV (85). This observation
is consistent with a marked response in serum markers of bone
metabolism. On the other hand, the magnitude of the objective
response rate was not significantly related to the treatment
strategy. Furthermore, patients treated by teriparatide in the 12-
month extension study showed further improvement in terms
of spine aBMD (total increase from baseline 7.1–14.4%), which
was higher in those initially randomized to teriparatide. Taken
together, teriparatide administration is related to an increased
spine aBMD skeletal activity and its activity is not increased by
vibration stimulation in chronic SCI individuals.
FUTURE PERSPECTIVES
Despite the progress that has been made in the field of
regenerative spinal cord medicine, the majority of SCI patients
continue to experience not only the direct neurological damage
but also the clinically relevant secondary complications affecting
the muscle and bone tissues. Due to the scarcity of available
data, attention should be paid in making strong statements
or recommendations for the management of these patients.
However, it is anyway possible to translate some of the existing
information into real-life clinical practice and to outline the
future directions for primary research and clinical studies. The
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FIGURE 2 | Bone and Muscle therapeutic interventions in SCI animal models and human subjects.
main bone and muscle therapeutic interventions in SCI animal
models and human subjects are outlined in (Figure 2).
Given that the bone and muscle tissues share not only
their origin from the mesenchymal multipotent stem cell but
also important signaling pathways, response to mechanical
stimulation, and complications, it is reasonable to conceive
that treatments should ideally target both tissues. From
this perspective, physical exercise, nutrition, and electrical
stimulation seem to be the most promising and rational way
of treating both muscle atrophy and osteoporosis. In particular,
the epidural electrical stimulation has the interesting potential of
fostering both the neurological recovery and the increase of the
muscle mass. Hormonal treatments represent another valuable
option but their safety profile needs to be investigated in the
long term.
Another future therapeutic option might be the modulation
of microRNAs (miRNAs) which are non-coding RNA molecules
involved in transcriptional regulation that target pathways of
human diseases. They might be considered not only a target
to prevent bone and muscle modifications but also a potential
powerful therapeutic intervention in improving the functional
recovery after SCI. In this regard, it has been recently showed how
miRNA-411 andmiRNA-340-5p increase could reduce apoptosis,
gliosis and glial scar formation, and all the inflammators in SCI
rats (86, 87).
CONCLUSIONS
SCIs encompass a wide variety of abnormal conditions that
reverberate at the musculoskeletal level. Many secondary
modifications show similarities and shared pathophysiological
patterns to both muscle and bone tissues. The limited evidences
in the literature summarized in this review suggests the need
of an early start of any therapeutic intervention. However, clear
evidence about the most effective treatment to counter bone and
muscle modifications after SCI is missing.
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A deeper understanding of the bone and muscle
interactions would improve the outcome of the patients
affected by several conditions related to musculoskeletal
changes, such as SCI, aging, space travels, and prolonged
immobility. Additional insights in bone and muscle
interactions will be germane for the development
of multitargeted specific therapeutic and preventive
strategies acting on both bone and muscle tissue. The
development of multidisciplinary recommendations is
required for the clinical management of these patients at
an individualized level.
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